NO984084L - 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof - Google Patents
4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereofInfo
- Publication number
- NO984084L NO984084L NO984084A NO984084A NO984084L NO 984084 L NO984084 L NO 984084L NO 984084 A NO984084 A NO 984084A NO 984084 A NO984084 A NO 984084A NO 984084 L NO984084 L NO 984084L
- Authority
- NO
- Norway
- Prior art keywords
- amino
- preparation
- pyrimidine derivatives
- compounds
- medicaments containing
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
Landscapes
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Dermatology (AREA)
- Immunology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Den foreliggende oppfinnelse vedrører 4-amino-pyrimidin-derivater med den generelle formel hvor Ra. Rb- A og B er som definert i krav 1, deres tautomerer, deres stereoisomerer og deres salter, spesielt deres fysiologisk akseptable salter med uorganiske eller organiske syrer eller baser, og som har verdifulle farmakologiske egenskaper, særlig en hemmende virkning på signaltransduksjonen formidlet gjennom tyrosin- kinaser, deres anvendelse for behandling av sykdommer, særlig tumorsykdom- mer, og deres fremstilling.The present invention relates to 4-amino-pyrimidine derivatives of the general formula wherein Ra. Rb-A and B are as defined in claim 1, their tautomers, their stereoisomers and their salts, especially their physiologically acceptable salts with inorganic or organic acids or bases, and which have valuable pharmacological properties, in particular an inhibitory effect on the signal transduction mediated through tyrosine. - kinases, their use in the treatment of diseases, especially tumor diseases, and their preparation.
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE1996108631 DE19608631A1 (en) | 1996-03-06 | 1996-03-06 | New (heterocyclyl- pyrimidino or -pyrido)fused pyrimidine derivatives |
| DE19629652A DE19629652A1 (en) | 1996-03-06 | 1996-07-23 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and processes for their preparation |
| PCT/EP1997/001057 WO1997032881A1 (en) | 1996-03-06 | 1997-03-03 | 4-amino pyrimidine derivates, medicaments containing these compounds, their use and process for their production |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| NO984084D0 NO984084D0 (en) | 1998-09-04 |
| NO984084L true NO984084L (en) | 1998-09-04 |
Family
ID=26023531
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO984084A NO984084L (en) | 1996-03-06 | 1998-09-04 | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof |
Country Status (19)
| Country | Link |
|---|---|
| EP (1) | EP0885226A1 (en) |
| JP (1) | JP2000506847A (en) |
| KR (1) | KR19990087550A (en) |
| CN (1) | CN1212695A (en) |
| AU (1) | AU710274B2 (en) |
| BG (1) | BG102708A (en) |
| BR (1) | BR9708312A (en) |
| CA (1) | CA2243994A1 (en) |
| CZ (1) | CZ281798A3 (en) |
| DE (1) | DE19629652A1 (en) |
| EE (1) | EE9800277A (en) |
| HU (1) | HUP9901820A3 (en) |
| IL (1) | IL125404A0 (en) |
| NO (1) | NO984084L (en) |
| NZ (1) | NZ331546A (en) |
| PL (1) | PL328771A1 (en) |
| SK (1) | SK120598A3 (en) |
| TR (1) | TR199801749T2 (en) |
| WO (1) | WO1997032881A1 (en) |
Families Citing this family (97)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| AU719434B2 (en) | 1996-02-13 | 2000-05-11 | Astrazeneca Ab | Quinazoline derivatives as VEGF inhibitors |
| ES2169355T3 (en) | 1996-03-05 | 2002-07-01 | Astrazeneca Ab | DERIVATIVES OF 4-ANILINOQUINAZOLINA. |
| UA71945C2 (en) * | 1999-01-27 | 2005-01-17 | Pfizer Prod Inc | Substituted bicyclic derivatives being used as anticancer agents |
| EP1396489A1 (en) * | 1999-01-27 | 2004-03-10 | Pfizer Products Inc. | Heteroaromatic bicyclic derivatives useful as anticancer agents |
| EP1676845B1 (en) | 1999-11-05 | 2008-06-11 | AstraZeneca AB | New quinazoline derivatives |
| US7407970B2 (en) | 2003-06-24 | 2008-08-05 | Neurosearch A/S | 8-aza-bicyclo[3.2.1]octane derivatives and their use as monoamine neurotransmitter re-uptake inhibitors |
| MX2007010068A (en) * | 2005-02-16 | 2007-10-10 | Schering Corp | Piperazine-piperidines with cxcr3 antagonist activity. |
| EP2349235A1 (en) | 2008-11-07 | 2011-08-03 | Triact Therapeutics, Inc. | Use of catecholic butane derivatives in cancer therapy |
| EP2352732B1 (en) * | 2008-12-01 | 2013-02-20 | Merck Patent GmbH | 2,5-DIAMINO-SUBSTITUTED PYRIDO[4, 3-d]PYRIMIDINES AS AUTOTAXIN INHIBITORS AGAINST CANCER |
| WO2010099139A2 (en) | 2009-02-25 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Combination anti-cancer therapy |
| JP2012519170A (en) | 2009-02-26 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | INSITU method for monitoring EMT status of tumor cells in vivo |
| US8465912B2 (en) | 2009-02-27 | 2013-06-18 | OSI Pharmaceuticals, LLC | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012519281A (en) | 2009-02-27 | 2012-08-23 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Methods for identifying mesenchymal tumor cells or agents that inhibit their production |
| WO2010099138A2 (en) | 2009-02-27 | 2010-09-02 | Osi Pharmaceuticals, Inc. | Methods for the identification of agents that inhibit mesenchymal-like tumor cells or their formation |
| JP2012520893A (en) | 2009-03-18 | 2012-09-10 | オーエスアイ・ファーマシューティカルズ，エルエルシー | Combination cancer treatment comprising administration of an EGFR inhibitor and an IGF-1R inhibitor |
| EP2510110A1 (en) | 2009-11-13 | 2012-10-17 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| EP2468883A1 (en) | 2010-12-22 | 2012-06-27 | Pangaea Biotech S.L. | Molecular biomarkers for predicting response to tyrosine kinase inhibitors in lung cancer |
| US9134297B2 (en) | 2011-01-11 | 2015-09-15 | Icahn School Of Medicine At Mount Sinai | Method and compositions for treating cancer and related methods |
| EP2492688A1 (en) | 2011-02-23 | 2012-08-29 | Pangaea Biotech, S.A. | Molecular biomarkers for predicting response to antitumor treatment in lung cancer |
| WO2012129145A1 (en) | 2011-03-18 | 2012-09-27 | OSI Pharmaceuticals, LLC | Nscle combination therapy |
| WO2012149014A1 (en) | 2011-04-25 | 2012-11-01 | OSI Pharmaceuticals, LLC | Use of emt gene signatures in cancer drug discovery, diagnostics, and treatment |
| BR112014004762A2 (en) | 2011-08-31 | 2018-06-19 | Genentech Inc | methods of determining tumor cell growth sensitivity to inhibition by an egfr kinase inhibitor, identifying a cancer patient who is likely to benefit from treatment with an efgr inhibitor, treating cancer in a patient, selecting a therapy for a cancer patient and determining erbb2 gene overexpression in a cell |
| SG11201400996SA (en) | 2011-09-30 | 2014-04-28 | Genentech Inc | Diagnostic methylation markers of epithelial or mesenchymal phenotype and response to egfr kinase inhibitor in tumours or tumour cells |
| WO2013152252A1 (en) | 2012-04-06 | 2013-10-10 | OSI Pharmaceuticals, LLC | Combination anti-cancer therapy |
| WO2013190089A1 (en) | 2012-06-21 | 2013-12-27 | Pangaea Biotech, S.L. | Molecular biomarkers for predicting outcome in lung cancer |
| EP2961412A4 (en) | 2013-02-26 | 2016-11-09 | Triact Therapeutics Inc | Cancer therapy |
| WO2014147246A1 (en) | 2013-03-21 | 2014-09-25 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Method and pharmaceutical composition for use in the treatment of chronic liver diseases associated with a low hepcidin expression |
| US9381246B2 (en) | 2013-09-09 | 2016-07-05 | Triact Therapeutics, Inc. | Cancer therapy |
| WO2015156674A2 (en) | 2014-04-10 | 2015-10-15 | Stichting Het Nederlands Kanker Instituut | Method for treating cancer |
| EP3699290A1 (en) | 2014-12-24 | 2020-08-26 | F. Hoffmann-La Roche AG | Therapeutic, diagnostic, and prognostic methods for cancer |
| EA201991528A1 (en) | 2016-12-22 | 2020-01-16 | Эмджен Инк. | Benzisothiazole, isothiazole [3,4-b] pyridine, quinazoline, phthalazine, pyrido [2,3-d] pyridazine and pyrido [2,3-d] pyrimidine derivatives in a red herbal solution COLORECTAL CANCER |
| JOP20190272A1 (en) | 2017-05-22 | 2019-11-21 | Amgen Inc | Kras g12c inhibitors and methods of using the same |
| ES2985118T3 (en) | 2017-09-08 | 2024-11-04 | Amgen Inc | KRAS G12C inhibitors and methods of using them |
| EP3788038B1 (en) | 2018-05-04 | 2023-10-11 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| CA3099118A1 (en) | 2018-05-04 | 2019-11-07 | Amgen Inc. | Kras g12c inhibitors and methods of using the same |
| MA52564A (en) | 2018-05-10 | 2021-03-17 | Amgen Inc | KRAS G12C INHIBITORS FOR CANCER TREATMENT |
| MX2020012731A (en) | 2018-06-01 | 2021-02-22 | Amgen Inc | Kras g12c inhibitors and methods of using the same. |
| EP4268898A3 (en) | 2018-06-11 | 2024-01-17 | Amgen Inc. | Kras g12c inhibitors for treating cancer |
| EP3807276B1 (en) | 2018-06-12 | 2025-12-10 | Amgen Inc. | Kras g12c inhibitors encompassing a piperazine ring and use thereof in the treatment of cancer |
| EP3860608A1 (en) | 2018-10-04 | 2021-08-11 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Egfr inhibitors for treating keratodermas |
| JP7516029B2 (en) | 2018-11-16 | 2024-07-16 | アムジエン・インコーポレーテツド | Improved synthesis of key intermediates for KRAS G12C inhibitor compounds |
| JP7454572B2 (en) | 2018-11-19 | 2024-03-22 | アムジエン・インコーポレーテツド | KRAS G12C inhibitor and its use |
| JP7377679B2 (en) | 2018-11-19 | 2023-11-10 | アムジエン・インコーポレーテツド | Combination therapy comprising a KRASG12C inhibitor and one or more additional pharmaceutically active agents for the treatment of cancer |
| KR102875569B1 (en) | 2018-12-20 | 2025-10-23 | 암젠 인크 | KIF18A inhibitor |
| US12441736B2 (en) | 2018-12-20 | 2025-10-14 | Amgen Inc. | KIF18A inhibitors |
| MX419368B (en) | 2018-12-20 | 2025-01-14 | Amgen Inc | Heteroaryl amides useful as kif18a inhibitors |
| US12459932B2 (en) | 2018-12-20 | 2025-11-04 | Amgen Inc. | KIF18A inhibitors |
| EP3930845A1 (en) | 2019-03-01 | 2022-01-05 | Revolution Medicines, Inc. | Bicyclic heterocyclyl compounds and uses thereof |
| WO2020180768A1 (en) | 2019-03-01 | 2020-09-10 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| EP3738593A1 (en) | 2019-05-14 | 2020-11-18 | Amgen, Inc | Dosing of kras inhibitor for treatment of cancers |
| KR20250159270A (en) | 2019-05-21 | 2025-11-10 | 암젠 인크 | Solid state forms |
| WO2021026100A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Pyridine derivatives as kif18a inhibitors |
| WO2021026101A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| EP4007752B1 (en) | 2019-08-02 | 2025-09-24 | Amgen Inc. | Kif18a inhibitors |
| WO2021026099A1 (en) | 2019-08-02 | 2021-02-11 | Amgen Inc. | Kif18a inhibitors |
| MX2022004656A (en) | 2019-10-24 | 2022-05-25 | Amgen Inc | PYRIDOPYRIMIDINE DERIVATIVES USEFUL AS INHIBITORS OF KRAS G12C AND KRAS G12D IN THE TREATMENT OF CANCER. |
| CN114901366A (en) | 2019-11-04 | 2022-08-12 | 锐新医药公司 | RAS inhibitors |
| KR20220109408A (en) | 2019-11-04 | 2022-08-04 | 레볼루션 메디슨즈, 인크. | RAS inhibitors |
| PH12022550988A1 (en) | 2019-11-04 | 2023-10-09 | Revolution Medicines Inc | Ras inhibitors |
| WO2021092115A1 (en) | 2019-11-08 | 2021-05-14 | Revolution Medicines, Inc. | Bicyclic heteroaryl compounds and uses thereof |
| AR120457A1 (en) | 2019-11-14 | 2022-02-16 | Amgen Inc | ENHANCED SYNTHESIS OF KRAS G12C INHIBITOR COMPOUND |
| CA3161156A1 (en) | 2019-11-14 | 2021-05-20 | Amgen Inc. | Improved synthesis of kras g12c inhibitor compound |
| WO2021108683A1 (en) | 2019-11-27 | 2021-06-03 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| WO2021142026A1 (en) | 2020-01-07 | 2021-07-15 | Revolution Medicines, Inc. | Shp2 inhibitor dosing and methods of treating cancer |
| MX2022016355A (en) | 2020-06-18 | 2023-04-03 | Revolution Medicines Inc | Methods for delaying, preventing, and treating acquired resistance to ras inhibitors. |
| CA3187757A1 (en) | 2020-09-03 | 2022-03-24 | Ethan AHLER | Use of sos1 inhibitors to treat malignancies with shp2 mutations |
| IL301298A (en) | 2020-09-15 | 2023-05-01 | Revolution Medicines Inc | Indole derivatives as ras inhibitors in the treatment of cancer |
| AU2021409816A1 (en) | 2020-12-22 | 2023-07-06 | Qilu Regor Therapeutics Inc. | Sos1 inhibitors and uses thereof |
| WO2022221227A1 (en) | 2021-04-13 | 2022-10-20 | Nuvalent, Inc. | Amino-substituted heterocycles for treating cancers with egfr mutations |
| WO2022235866A1 (en) | 2021-05-05 | 2022-11-10 | Revolution Medicines, Inc. | Covalent ras inhibitors and uses thereof |
| AR125782A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR125787A1 (en) | 2021-05-05 | 2023-08-16 | Revolution Medicines Inc | RAS INHIBITORS |
| AR127308A1 (en) | 2021-10-08 | 2024-01-10 | Revolution Medicines Inc | RAS INHIBITORS |
| CN119212994A (en) | 2021-12-17 | 2024-12-27 | 建新公司 | Pyrazolopyrazine compounds as SHP2 inhibitors |
| EP4227307A1 (en) | 2022-02-11 | 2023-08-16 | Genzyme Corporation | Pyrazolopyrazine compounds as shp2 inhibitors |
| JP2025509217A (en) | 2022-03-07 | 2025-04-11 | アムジエン・インコーポレーテツド | Process for preparing 4-methyl-2-propan-2-yl-pyridine-3-carbonitrile |
| WO2023172940A1 (en) | 2022-03-08 | 2023-09-14 | Revolution Medicines, Inc. | Methods for treating immune refractory lung cancer |
| CN120504682A (en) | 2022-06-10 | 2025-08-19 | 锐新医药公司 | Macrocyclic RAS inhibitors |
| JP2025536257A (en) | 2022-10-14 | 2025-11-05 | ブラック ダイアモンド セラピューティクス，インコーポレイティド | Methods of treating cancer using isoquinoline or 6-AZA-quinoline derivatives |
| KR20250164828A (en) | 2023-03-30 | 2025-11-25 | 레볼루션 메디슨즈, 인크. | Composition for inducing RAS GTP hydrolysis and use thereof |
| KR20260005904A (en) | 2023-04-07 | 2026-01-12 | 레볼루션 메디슨즈, 인크. | macrocyclic RAS inhibitors |
| CN121263418A (en) | 2023-04-07 | 2026-01-02 | 锐新医药公司 | Macrocyclic RAS inhibitors |
| TW202448897A (en) | 2023-04-14 | 2024-12-16 | 美商銳新醫藥公司 | Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof |
| CN121100123A (en) | 2023-04-14 | 2025-12-09 | 锐新医药公司 | Crystalline form of Ras inhibitors |
| TW202508595A (en) | 2023-05-04 | 2025-03-01 | 美商銳新醫藥公司 | Combination therapy for a ras related disease or disorder |
| US20250049810A1 (en) | 2023-08-07 | 2025-02-13 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025080946A2 (en) | 2023-10-12 | 2025-04-17 | Revolution Medicines, Inc. | Ras inhibitors |
| TW202542151A (en) | 2023-12-22 | 2025-11-01 | 美商銳格醫藥有限公司 | Sos1 inhibitors and uses thereof |
| WO2025171296A1 (en) | 2024-02-09 | 2025-08-14 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025240847A1 (en) | 2024-05-17 | 2025-11-20 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2025255438A1 (en) | 2024-06-07 | 2025-12-11 | Revolution Medicines, Inc. | Methods of treating a ras protein-related disease or disorder |
| WO2025265060A1 (en) | 2024-06-21 | 2025-12-26 | Revolution Medicines, Inc. | Therapeutic compositions and methods for managing treatment-related effects |
| WO2026006747A1 (en) | 2024-06-28 | 2026-01-02 | Revolution Medicines, Inc. | Ras inhibitors |
| WO2026015825A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Use of ras inhibitor for treating pancreatic cancer |
| WO2026015790A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015796A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
| WO2026015801A1 (en) | 2024-07-12 | 2026-01-15 | Revolution Medicines, Inc. | Methods of treating a ras related disease or disorder |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| IL112249A (en) * | 1994-01-25 | 2001-11-25 | Warner Lambert Co | Pharmaceutical compositions containing di and tricyclic pyrimidine derivatives for inhibiting tyrosine kinases of the epidermal growth factor receptor family and some new such compounds |
| DE4431867A1 (en) * | 1994-09-07 | 1996-03-14 | Thomae Gmbh Dr K | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and processes for their preparation |
-
1996
- 1996-07-23 DE DE19629652A patent/DE19629652A1/en not_active Ceased
-
1997
- 1997-03-03 CN CN97192787A patent/CN1212695A/en active Pending
- 1997-03-03 PL PL97328771A patent/PL328771A1/en unknown
- 1997-03-03 WO PCT/EP1997/001057 patent/WO1997032881A1/en not_active Ceased
- 1997-03-03 JP JP9531444A patent/JP2000506847A/en active Pending
- 1997-03-03 AU AU19251/97A patent/AU710274B2/en not_active Ceased
- 1997-03-03 EE EE9800277A patent/EE9800277A/en unknown
- 1997-03-03 TR TR1998/01749T patent/TR199801749T2/en unknown
- 1997-03-03 SK SK1205-98A patent/SK120598A3/en unknown
- 1997-03-03 CA CA002243994A patent/CA2243994A1/en not_active Abandoned
- 1997-03-03 EP EP97907066A patent/EP0885226A1/en not_active Ceased
- 1997-03-03 BR BR9708312A patent/BR9708312A/en not_active IP Right Cessation
- 1997-03-03 HU HU9901820A patent/HUP9901820A3/en unknown
- 1997-03-03 CZ CZ982817A patent/CZ281798A3/en unknown
- 1997-03-03 NZ NZ331546A patent/NZ331546A/en unknown
- 1997-03-03 KR KR1019980706987A patent/KR19990087550A/en not_active Withdrawn
- 1997-03-03 IL IL12540497A patent/IL125404A0/en unknown
-
1998
- 1998-08-20 BG BG102708A patent/BG102708A/en unknown
- 1998-09-04 NO NO984084A patent/NO984084L/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| DE19629652A1 (en) | 1998-01-29 |
| CN1212695A (en) | 1999-03-31 |
| JP2000506847A (en) | 2000-06-06 |
| TR199801749T2 (en) | 1998-12-21 |
| EE9800277A (en) | 1999-02-15 |
| KR19990087550A (en) | 1999-12-27 |
| IL125404A0 (en) | 1999-03-12 |
| NO984084D0 (en) | 1998-09-04 |
| AU1925197A (en) | 1997-09-22 |
| CA2243994A1 (en) | 1997-09-12 |
| EP0885226A1 (en) | 1998-12-23 |
| BR9708312A (en) | 1999-08-03 |
| AU710274B2 (en) | 1999-09-16 |
| HUP9901820A3 (en) | 2001-10-29 |
| SK120598A3 (en) | 1999-06-11 |
| BG102708A (en) | 1999-09-30 |
| NZ331546A (en) | 2000-03-27 |
| WO1997032881A1 (en) | 1997-09-12 |
| CZ281798A3 (en) | 1999-02-17 |
| HUP9901820A2 (en) | 1999-09-28 |
| PL328771A1 (en) | 1999-02-15 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO984084L (en) | 4-Amino-pyrimidine derivatives, medicaments containing these compounds, their use and method of preparation thereof | |
| MY123642A (en) | Bicyclic heterocyclic compounds, pharmaceutical compositions containing these compounds, and processes for preparing them. | |
| NO984081L (en) | Pyrimido [5,4-d] pyrimidines, medicaments containing these compounds, their use and method of preparation thereof | |
| CA2375259A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| CA2417652A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| NO940261L (en) | 5-membered heterocycles, process for the preparation thereof and drugs containing these compounds | |
| CA2417897A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| NO933248L (en) | Cyclic urea derivatives, drugs containing these compounds, and process for their preparation | |
| MY136086A (en) | Quinazoline derivatives, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| BG105765A (en) | 4-AMINO-HYANZOLINE AND XINOLINE DERIVATIVES WITH INHIBITORS ON SIGNAL TRANSLATION, THERAPISED BY TYROSINKINASES | |
| NO307833B1 (en) | Pyrimido [5,4-d] pyrimidines, physiologically acceptable salts, drugs containing these compounds and their use | |
| CA2417050A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| NO991732L (en) | New heterocyclylmethyl substituted pyrazole derivatives | |
| CA2403152A1 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| MX9807073A (en) | Pyrimido[5,4-d]pyrimidines, medicaments containing these compounds, their use and process for their production | |
| NO920957L (en) | CYCLE URINARY DERIVATIVES AND PHARMACEUTICALS CONTAINING THESE COMPOUNDS | |
| NO972881L (en) | Piperazine derivatives, drugs containing them, their use and methods for their preparation | |
| NO992400L (en) | New substituted pyrazole derivatives | |
| NO934501L (en) | Carboxylic acid derivatives, drugs containing these compounds, and process for their preparation | |
| AU2001295482A1 (en) | Bicyclic heterocycles, medicaments containing these compounds, their use, and methods for the production thereof | |
| WO2000055162A3 (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| NO931527L (en) | CYCLIC IMINO DERIVATIVES, MEDICINAL PREPARATIONS CONTAINING THESE, AND PROCEDURE FOR THEIR PREPARATION | |
| AU5500896A (en) | Substituted phenylamidines, pharmaceutical compositions containing these compounds and processes for preparing them | |
| MY140484A (en) | Bicyclic heterocycles, pharmaceutical compositions containing these compounds, their use and processes for preparing them | |
| YU60501A (en) | 4-amino-quinazoline and quinoline derivatives having an inhibitory effect on signal transduction mediated by tyrosine kinases |